血清高迁移率族蛋白B1在非霍奇金淋巴瘤中的表达和意义

Expression and clinical significance of high mobility group protein B1 in non-Hodgkin lymphoma

目的探索非霍奇金淋巴瘤患者血清中高迁移率族蛋白B1(HMGB1)的表达水平,以及其与疗效和预后的关系。方法采用ELISA方法检测37例非霍奇金淋巴瘤患者初始治疗前、化疗后的HMGB1水平,并以35例健康体检者为对照。结果非霍奇金淋巴瘤患者初治前血清中HMGB1水平显著高于健康体检者,差异有统计学意义(P<0.05);化疗后缓解(部分缓解或完全缓解)的非霍奇金淋巴瘤患者血清HMGB1水平较初治前明显降低,差异有统计学意义(P<0.05)。HMGB1呈递减趋势的非霍奇淋巴瘤患者的生存时间较HMGB1呈递增趋势的非霍奇金淋巴瘤患者明显延长。结论血清HMGB1水平与非霍奇金淋巴瘤的发病和发展密切相关,检测血清HMGB1水平有助于了解患者的病情变化及转归。

Objective To investigate the relation between the serum level of high mobility group protein B1 （ HMGBl ） and the curative effect and prognosis in non Hodgkin lymphoma. Methods The ser- um level of HMGBI was evaluated with ELISA in 37 non Hodgkin lymphoma patients and 35 healthy per- sons. Results The HMGB1 level of non-Hodgkin lymphoma patients（pre-chemotherapy） was much high- er than that of control group（ P 〈 0. 05 ） ; the HMGB1 level of the patients（ partial remission or complete re- mission） after chemotherapy was significantly lower than before （P 〈 O. 05 ）; the survival time of patients with decreasing trend in HMGB1 was significantly prolonged compared with the patients with increasing trend in HMGB1. Conclusions The serum level of HMGB1 is closely related to the pathogenesis, develop- ment of non-Hodgkin lymphoma, and the evaluation of serum HMGB1 level is helpful for understanding the patient＇s condition and prognosis.